Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000954527
Ethics application status
Approved
Date submitted
18/07/2024
Date registered
6/08/2024
Date last updated
6/08/2024
Date data sharing statement initially provided
6/08/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
The CUTE Project - CUT umbilical cord milking to prevent Encephalopathy in infants with prenatal drug exposure
Query!
Scientific title
CUT umbilical cord milking to prevent Encephalopathy in infants with prenatal drug exposure
Query!
Secondary ID [1]
312557
0
2023/PID02555
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CUTE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prenatal opioid exposure
334453
0
Query!
Inflammation in neonate
334465
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
331073
331073
0
0
Query!
Fetal medicine and complications of pregnancy
Query!
Reproductive Health and Childbirth
331074
331074
0
0
Query!
Childbirth and postnatal care
Query!
Mental Health
331075
331075
0
0
Query!
Addiction
Query!
Inflammatory and Immune System
331159
331159
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Umbilical cord milking (UCM) - 32 opioid-using mothers will be randomly assigned to receive umbilical cord milking or standard cord clamping in the 2 weeks prior to birth. The Research Midwife/PI will be responsible for ensuring that the correct cord clamping technique is employed through notation on hospital records. An information sheet and video will be provided to all staff involved. Formal training will not be provided unless requested by staff. Note that this is a variation of normal cord clamping procedures, and does not disrupt the birth process.
Infants randomized to the UCM condition will have their umbilical cord clamped 20-30 cm from their body within 30-60 seconds of birth. The cord will then be cut, leaving the long section attached to the infant. This section of the cord will be squeezed slowly (‘milked’) towards the infant once or twice to push the blood within inside the infant’s body. The cord is then clamped closer to the infant and care proceeds as usual. Once each cord is milked, it will be measured (cut end to infant umbilicus).
Standard (or immediate) cord clamping refers to clamping of the cord within 15-60 seconds of birth (WHO).
Query!
Intervention code [1]
329071
0
Treatment: Other
Query!
Comparator / control treatment
16 pregnant women with no history of substance use across pregnancy will be recruited. No UCM will be administered to control participants, they will receive standard cord clamping. Standard (or immediate) cord clamping refers to clamping of the cord within 15-60 seconds of birth (WHO).
There is no control group receiving UCM in this design for two reasons: 1) obstetric and midwife staff conclude it would be difficult to recruit otherwise healthy pregnant women to receive UCM; 2) there would be a ceiling effect in these infants where UCM would not noticeably improve outcomes. Nonetheless, the control group is essential to provide a baseline reading across all measures while controlling for all external factors (e.g., socio-economic status) and to indicate a direction of change for the measures to be gathered i.e. whether infant inflammatory cytokines are higher or lower compared to controls, and whether the UCM normalises these values.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
338836
0
Change in inflammatory markers in blood, saliva and placental samples. Inflammatory markers assessed as a composite primary outcome.
Markers of interest: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-?, IL-1ß, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1 (MCAF), MIP-1a, MIP-1ß, PDGF-BB, RANTES, TNF-a, VEGF, DRD2, CXCL1, CCL2, TLR4, NLRP3, SERT, TPH1, IDO.
Query!
Assessment method [1]
338836
0
Cytokine analysis and immunoassays
Query!
Timepoint [1]
338836
0
Maternal blood collected = Antenatal (~32 weeks)
Infant and cord blood collected = At birth and postnatal (during heel-prick)
Saliva collected = Postnatal (2-3 days post-birth)
Placental biopsies = At birth
All of these samples will be analysed at a later date. Inflammatory markers assessed as a composite primary outcome.
Query!
Primary outcome [2]
338845
0
Presence of inflammatory gut microbiota. Samples assessed as a composite primary outcome.
Query!
Assessment method [2]
338845
0
Microbiome stool analysis from maternal and infant stool samples.
16s rRNA sequencing used to identify and bacterial diversity. v3-v4 amplicon library prep to be used.
Query!
Timepoint [2]
338845
0
Maternal stool = antenatal (~32 weeks gestation)
Infant stool = Postnatal (2-3 days post-birth), 3-months postnatal
Samples analysed at a later date.
Query!
Secondary outcome [1]
437662
0
Frequency of abnormal scores on neuro-behavioural assessment (GMA)
Query!
Assessment method [1]
437662
0
General Movement Assessment (GMA)
Query!
Timepoint [1]
437662
0
3-months postnatal
Query!
Secondary outcome [2]
437663
0
Mean brain volume and frequency of abnormalities in white and grey matter structure. This will be assessed as a composite outcome.
Query!
Assessment method [2]
437663
0
MRI
Query!
Timepoint [2]
437663
0
Within first 2 weeks of birth
Query!
Secondary outcome [3]
437664
0
Rate of physical growth
Query!
Assessment method [3]
437664
0
Anthropometric data - Birth weight assessed using a scale, length assessed using an infant measuring mat and head circumference assessed using a tape measure.
This will be assessed as a composite outcome.
Query!
Timepoint [3]
437664
0
Birth weight, length and head circumference measured at birth, at weekly medical appointments 1-8 weeks post-birth, and 3-months.
Query!
Secondary outcome [4]
438195
0
Cognitive, emotion and motor development at 3 months
Query!
Assessment method [4]
438195
0
General Movement Assessment (GMA) at 3-months
Query!
Timepoint [4]
438195
0
3-months = GMA video to be submitted by participant
Query!
Eligibility
Key inclusion criteria
Opioid-using mothers-
1) 18-35 yrs, healthy weight (BMI 25-29.9; Australian Institute of Health and Welfare, 2023)
2) Singleton pregnancy
3) Willingness and ability to give written informed consent prior to birth
4) Willingness to participate in and comply with the study
5) Use of opiates (heroin, methadone, buprenorphine, codeine, oxycodone, fentanyl, tramadol, pethidine) during pregnancy as confirmed via self-report and/or maternal and neonatal urine toxicology
Non opioid-using mothers-
1-4 as above
5) No use of substances (e.g. opiates) during pregnancy as confirmed via self-report and/or maternal and neonatal urine toxicology
Infant-
1) Born at >39-41 weeks of gestation (or, if gestation unknown, an estimated birthweight of greater than or equal to 2.5 kg)
Query!
Minimum age
0
Years
Query!
Query!
Maximum age
35
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Maternal-
HIV positive status, diabetes
Complications with pregnancy (e.g. gestational diabetes, pre-eclampsia, chorioamnionitis)
Chromosomal, inflammatory or autoimmune disorders with or without medication
Use of any anti-inflammatory or steroid medications
Consent unable to be obtained before birth (e.g., insufficient time, precipitous labour, cognitive impairment, inebriation)
Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
Infant-
Non-vigorous status at birth
Major congenital or chromosomal anomalies
Auto-immune or infectious diseases
Admission to NICU or requiring ventilatory support
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation randomised on RedCap server by project manager.
Allocation only revealed to CPI and project manager.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by Excel
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Opioid-using mothers randomly allocated to umbilical-cord milking (UCM) or standard cord clamping (SCC) conditions. Simple randomisation via RedCap secure platform using a randomisation table created by Excel.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
30/08/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/08/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
30/11/2025
Query!
Actual
Query!
Sample size
Target
96
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
26812
0
Liverpool Hospital - Liverpool
Query!
Recruitment postcode(s) [1]
42863
0
2170 - Liverpool
Query!
Funding & Sponsors
Funding source category [1]
316983
0
Charities/Societies/Foundations
Query!
Name [1]
316983
0
The Ross Trust Foundation
Query!
Address [1]
316983
0
Query!
Country [1]
316983
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Dr Ju Lee Oei
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319233
0
None
Query!
Name [1]
319233
0
Query!
Address [1]
319233
0
Query!
Country [1]
319233
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315737
0
South Western Sydney Local Health District Human Research Ethics Committee
Query!
Ethics committee address [1]
315737
0
https://www.swslhd.health.nsw.gov.au/ethics/
Query!
Ethics committee country [1]
315737
0
Australia
Query!
Date submitted for ethics approval [1]
315737
0
02/10/2023
Query!
Approval date [1]
315737
0
20/12/2023
Query!
Ethics approval number [1]
315737
0
2023/ETH02217
Query!
Summary
Brief summary
The CUTE Project seeks to determine whether prenatal opioid exposure increases inflammation in neonates. The CUTE Project also seeks to determine whether umbilical cord milking (UCM) reduces inflammation in infants with prenatal opioid exposure, and whether it improves their postnatal developmental outcomes. UCM involves supplying the baby with the blood from their umbilical cord. 48 pregnant women will be recruited: 32 with histories of opioid use during pregnancy, and 16 without. At birth, half the opioid-exposed babies will be randomly assigned to receive UCM. Placenta, blood and saliva samples from all babies, and blood samples from all mothers, will be collected to assess immune functioning. Maternal and infant stool samples will also be collected to assess gut health. Urine from mothers and infants, and meconium, will be collected for toxicology analyses. Brain development will be measured through MRI scans of exposed babies, and behavioural testing of all babies. Compared to non-drug exposed controls, we hypothesise prenatal opioid exposure (POE) will be associated with systemic inflammation evident as increased proinflammatory markers in mother and infant blood and saliva. We hypothesise that both mother and infant with show evidence of gut dysbiosis. We hypothesise that infants with POE will have reduced brain volume and white matter density, and poorer cognitive, emotion and motor development at 3 months of age. Finally, we hypothesise that these measures will be inter-related, where infants with greater evidence of inflammation will have poorer outcomes on the MRI and 3-month follow-up. We hypothesise that UCM will reduce evidence of inflammation in the days following birth and that this will be related to improved outcomes at 3-month follow-up.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135654
0
Dr Ju Lee Oei
Query!
Address
135654
0
Department of Newborn Care Royal Hospital for Women Level 1 Barker Street Randwick NSW 2031
Query!
Country
135654
0
Australia
Query!
Phone
135654
0
+61 409228005
Query!
Fax
135654
0
Query!
Email
135654
0
[email protected]
Query!
Contact person for public queries
Name
135655
0
Ju Lee Oei
Query!
Address
135655
0
Department of Newborn Care Royal Hospital for Women Level 1 Barker Street Randwick NSW 2031
Query!
Country
135655
0
Australia
Query!
Phone
135655
0
+61 409228005
Query!
Fax
135655
0
Query!
Email
135655
0
[email protected]
Query!
Contact person for scientific queries
Name
135656
0
Ju Lee Oei
Query!
Address
135656
0
Department of Newborn Care Royal Hospital for Women Level 1 Barker Street Randwick NSW 2031
Query!
Country
135656
0
Australia
Query!
Phone
135656
0
+61 409228005
Query!
Fax
135656
0
Query!
Email
135656
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
24007
Ethical approval
388149-(Uploaded-18-07-2024-14-35-18)-Date of Decision Notification_APPROVAL_20.12.23.docx
24008
Study protocol
388149-(Uploaded-18-07-2024-14-43-45)-12. CUTE Project Study Protocol_v5_08.02.2024.docx
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF